A Phase 3, Open-Label Study of the Safety of HPN-100 for

Project: Research project

Description

A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
StatusFinished
Effective start/end date3/23/0912/31/11

Funding

  • Hyperion Therapeutics

Fingerprint

Inborn Urea Cycle Disorder
Safety
glycerol phenylbutyrate